News Hub | News Direct

News Release

IQ-AI Limited shares latest progress from Phase I glioblastoma clinical trial

IQ-AI Ltd

Dr Jennifer Connelly, the Principal Investigator (PI) of the IQ-AI Limited sponsored Phase I Clinical Trial that is being conducted at the Medical College of Wisconsin, joins Proactive's Natalie Stoberman to discuss the latest updates from its treatment for recurring glioblastoma patients. IQ-AI Ltd, the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

July 19, 2023 01:03 PM Eastern Daylight Time

Video

News Release

Race Oncology announces deal with manufacturer Ardena to develop company’s new IV formulation RC220

Race Oncology Ltd

Race Oncology CEO Damian Clark-Bruce joined Steve Darling from Proactive to share significant news about the company's recent agreements and partnerships. Firstly, Race Oncology has signed an agreement with Ardena Holding, a global contract development and manufacturing organization. This collaboration will provide additional Good Manufacturing Practice -standard manufacturing capability for its flagship IV formulation of bisantrene, RC220. Ardena is a fully integrated CDMO known for its expertise in assisting biopharma companies throughout the drug development life cycle, including the production of sterile injectable products for clinical development. Clark-Bruce further explained to Proactive that this partnership with Ardena strengthens Race Oncology's existing manufacturing programs, as it establishes a primary source for EU-compliant supplies of RC220. This is particularly important for EU clinical studies, ensuring the availability of high-quality, GMP-compliant formulations of RC220. Additionally, Clark-Bruce shared news about an exclusive license agreement with City of Hope, a prominent US cancer research and treatment organization. Through this agreement, Race Oncology gains access to City of Hope's intellectual property, which highlights bisantrene as a potent inhibitor of the human fat mass and obesity-associated protein. This discovery opens up new possibilities for exploring the therapeutic potential of bisantrene beyond its established use as an anti-cancer agent. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

July 19, 2023 12:52 PM Eastern Daylight Time

Video

Futura Medical "absolutely delighted" with US commercialisation agreement

Futura Medical PLC

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder speaks to Thomas Warner from Proactive London after announcing the signing of an agreement with Haleon to market Futura's topical, gel-based erectile dysfunction treatment MED3000. Barder says he's absolutely delighted with the agreement, which gives Futura access to the world's largest market for erectile dysfunction treatments. He gives a brief overview of the agreement, highlighting a $4 million upfront payment and milestone payments ranging from $5 million to $45 million. Barder emphasised the achievability of these milestones and mentioned that a royalty on all sales was also part of the agreement. In related news, Futura Medical announced a change in leadership with Non-Executive Chairman John Clarke stepping down to be succeeded by existing Non-Executive board member, Jeff Needham. Barder says that Needham has "real, relevant experience as we look to launch in the biggest market in the world with MED3000." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 19, 2023 10:52 AM Eastern Daylight Time

Video

New Policy Aims to Speed Kidney Acceptance Rates, Increase Transplants

United Network for Organ Sharing

The OPTN Board of Directors unanimously approved a new policy, that will help more patients receive a lifesaving kidney transplant by getting the right organ to the right patient faster. United Network for Organ Sharing (UNOS) is the non-profit organization that contracts with the federal government to serve as the nation’s Organ Procurement and Transplantation Network (OPTN). The new policy will improve the use of the OPTN offer filter tool, allowing offers of donor kidneys to arrive quicker to transplant programs that are most likely to accept them. The OPTN Offer Filters tool, which has been available to all U.S. kidney transplant programs since 2022 as an “opt in” resource, allows transplant teams to filter out organ offers that they don’t intend to accept. This allows time-sensitive offers to automatically go to patients at programs that have a history of accepting more medically complex organs. Currently, 60% of kidney programs have at least one filter turned on. The new “opt out” policy passed by the OPTN Board will automatically turn on offer filters specific to each kidney transplant program, based on the program’s acceptance history. Transplant programs will have the option to use these filters, remove them and create their own filters. Due to the continuously increasing number of organs recovered, as well as the diverse acceptance practices across transplant programs, some organ offers are extended to programs that may have never considered organs with certain clinical or donor characteristics. The use of offer filters is one strategy to help Organ Procurement Organizations (OPOs) allocate in the most efficient manner, while ensuring that transplant programs only receive offers that they have a history of considering and would legitimately consider. “The ongoing development of the offer filter tool is driven not only by feedback from the donation and transplant community, but by our own firmly held belief that we can never be satisfied with the status quo,” said Maureen McBride, UNOS CEO. “This new policy and the impact it will have on patients waiting for the gift of life is a critical step in our never-ending effort to drive improvement and save more lives.” Default filters are the first phase in a potential transition to mandatory offer filters, which were recommended by the National Academies of Sciences, Engineering and Medicine in its February 2022 report on the nation’s organ donation and transplantation system. The report identified offer acceptance as a “key area for improvement for transplant centers.” As the number of available organs continues to grow, so does the rate of organ non-use, particularly for kidneys, which are recovered before being accepted. By empowering transplant hospital staff with innovative new tools like offer filters and collaborative best practices, UNOS and the OPTN intend to maximize the potential of every donated organ and ultimately save more lives. Additional efforts to increase organ use Predictive Analytics utilizes waitlist and transplant candidate data at the time of a kidney offer to project when patients would receive additional offers, along with the patients’ likelihood of survival during that time without the initial offer. This information enables transplant teams to make informed decisions about the impacts of accepting or declining an organ offer. Transplant programs that participated in the predictive analytics pilot program demonstrated a 2.9 percentage point increase in offer acceptance compared to earlier. Transplant Vision (TxVx ), currently in early stages of development by UNOS Labs and a digital product development company, will leverage augmented reality technology to scan and digitally reconstruct recovered kidneys. This will help standardize high-quality organ imagery and other long-distance evaluation measurements, such as size and mass used by transplant center teams, to help determine whether to accept an organ offer. The Offer Acceptance Collaborative is an effort led by UNOS in its role as the OPTN. The collaborative has brought together transplant professionals from more than 80 adult and pediatric transplant programs to share effective practices and provide education on new data and analytical tools. Offer acceptance rates vary widely across the country. The collaborative seeks to bring together larger and small transplant programs from every region to learn from one another, improve organ offer evaluation and acceptance practices, and increase system efficiencies. Long-term results stemming from this work can help inform innovative solutions to organ non-use. By maximizing the utilization potential of each organ, we can increase the lifesaving impact that each deceased donor can make on the system. UNet Image Sharing is a digital platform developed by UNOS that allows organ procurement organizations (OPOs) to securely upload, view and share high-quality medical imaging studies with transplant hospitals. It is made available through UNet, the technology at the core of the donation and transplant system that powers patient registrations, donor referrals, organ matching and other essential functions used every day by transplant professionals. UNet Image Sharing was designed with community input that included a robust pilot program and is currently used by 79 percent of OPOs. It enables quicker, more confident decision-making by surgeons evaluating organ offers, which can increase organ acceptance rates and reduce inefficiencies during the organ allocation process. About UNOS United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

July 19, 2023 10:44 AM Eastern Daylight Time

Oxford Cannabinoid Technologies announces "potential breakthrough" in field of oncology

Oxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) Clarissa Sowemimo-Coker speaks to Thomas Warner from Proactive London after announcing what the prescription cannabinoid medicine company calls a "potential breakthrough" for the treatment of solid tumours. Sowemimo-Coker gives an overview of the announcements, highlighting promising early-stage data, promising, and says Oxford Cannabinoid Technologies is aiming to provide a convenient oral dose form for patients, significantly reducing costs and improving accessibility. The expansion into oncology aligns with OCT's strategy to explore various realms of medicine beyond their initial focus on pain. Sowemimo-Coker says that the company's collaboration agreement with Canopy Growth has already borne fruit, with more potential derivatives waiting to be explored. She also touches on the recent appointment of Dr. Tim Corn as Chief Medical Officer, with a view to advancing clinical trials and overall progress, and concludes by saying that an investor meeting is being held later this week. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 19, 2023 10:19 AM Eastern Daylight Time

Video

SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?

NanoViricides, Inc.

By David Willey, Benzinga Read the latest report on NanoViricides here. SARS-CoV-2 is not done yet — Although it is not grabbing as many headlines, the number of deaths are still greater than even a pandemic influenza year at last count. The virus is still lurking, causing COVID and long COVID. Former White House COVID czar Ashish Jha has said “There is a temptation to say it's all over and we don't have to think about COVID anymore. The way I look at it is the virus can still surprise us.” We have learnt just to live with it, thanks to the immunity from vaccines and from the viral infection itself. However, according to the World Health Organization (WHO), “Even in vaccinated individuals, uncertainties remain about the duration of protection, the effectiveness of current vaccines and the efficacy of existing treatments for COVID-19 against emerging SARS-CoV-2 variants and subvariants.” Despite over 300 clinical trials, there are only three approved drugs that remain. Unfortunately, each of them has limitations. Current Approved Therapies Have Significant Limitations Remdesivir, from Gilead Sciences (NASDAQ: GILD) has only received a conditional recommendation from the WHO for patients with severe COVID-19. Also, Remdesivir can only be administered as an infusion in a hospital, limiting the patient populations who can get access to the drug. Two other drugs, Molnupiravir by Merck & Co. (NYSE: MRK) and Paxlovid by Pfizer (NYSE: PFE) are both orally available. The WHO has issued a strong recommendation for Paxlovid, but only a conditional recommendation for Molnupivavir for patients with severe COVID-19 or non-severe COVID-19 at the highest risk of hospitalization. However, the WHO notes limitations to both of these drugs in its guidelines, and it also doesn’t advise certain populations to take these treatments on account of drug-to-drug interactions or other side effects. This indicates a need for a safer and more comprehensive treatment. A unique and novel drug that looks to fulfill this unmet medical need is NV-CoV-2, developed by NanoViricides, Inc. (NYSE American: NNVC). NanoViricides recently announced it has begun clinical trials for NV-CoV-2, an innovative treatment for patients with COVID-19. NanoViricides is developing a novel nanomedicine platform of antiviral therapies, and its leading drug candidate is NV-CoV-2, which contains API NV-387. Dr. Anil Diwan, President and CEO of NanoViricides, described the drug as an exciting opportunity to fill an “as-yet-unmet medical need of a highly effective broad-spectrum, anti-coronavirus drug that can be used for all patient populations.” The drug has already demonstrated a robust safety profile in pre-clinical animal safety and tolerability evaluations, as well as showing itself to be non-immunogenic and non-mutagenic in standard tests. These data suggest a potentially exciting feature of NV-CoV-2 in its ability to treat all patient populations. Now with the trial beginning, its primary outcomes include: “To evaluate the safety and tolerability with the initial administration of NV-CoV-2 in healthy human subjects,” and “To find the maximum tolerated dose for the support of phase-2 clinical trials.” It employs NV-387, a first-in-class chemical nanomedicine with a novel mechanism of action called the “Re-Infection Blocker” designed to entirely eliminate the virus from the patient’s system. The drug will be trialed on patients with mild to moderate COVID-19, in the Phase 1b part of the clinical trial, though the company believes this could also be efficacious for patients with severe coronavirus and even for hospitalized cases. Note that NV-CoV-2 has been shown to be significantly more effective than Remdesivir in lethal lung infection models of human coronavirus NL-63 in rodents. Remdesivir is the only drug currently approved for hospitalized cases. There are multiple formulations of NV-CoV-2, including as an oral syrup and oral gummy, for outpatient use, which broadens the patient population that could take this treatment. An injectable formulation was also developed for hospitalized patients. NanoViricides believes that the safety and efficacy of this drug could make it a popular choice, as some of the more popular alternative COVID-19 treatments available are either less safe or are contra-indicated for several classes of patients. According to NanoViricides, this opens up a huge market for its drug, NV-CoV-2. As a broad-spectrum anti-coronavirus drug with multiple formulations, it can be given to any patient group. Plus, its novel nanomedicine technology potentially makes it a highly effective treatment for COVID-19 as well as other coronaviruses. Learn more about how NanoViricides is tackling different viruses by visiting its website. About NanoViricides NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 info@nanoviricides.com Company Website http://www.nanoviricides.com

July 19, 2023 09:15 AM Eastern Daylight Time

Video

Le lancement du bioréacteur de The Cultivated B annonce la viabilité commerciale de l'industrie de l'agriculture cellulaire

The Cultivated B

The Cultivated B (TCB) a annoncé aujourd’hui le lancement de la production de son bioréacteur à application industrielle AUXO V™ sur le site de Burlington, dans l’Ontario, avec des délais de livraison réduits. Cette annonce représente une étape importante pour TCB, mais plus encore, répond au besoin urgent de l'industrie de l'agriculture cellulaire d'augmenter considérablement sa capacité de production mondiale afin d'atteindre une viabilité commerciale. Les délais actuels de livraison des bioréacteurs proposés par les autres fournisseurs pouvant atteindre jusqu’à deux ans, les producteurs de viandes cultivées, de médicaments et de produits de soins personnels utilisant l'agriculture cellulaire et la fermentation de précision sont confrontés à des défis pour passer de l’échelle laboratoire à la fabrication commerciale. TCB souhaite débloquer ce verrou industriel en offrant de nouveaux bioréacteurs, dont la conception innovante permet un usage simplifié pour les opérateurs, et avec des délais de livraison compétitifs de quelques semaines. « L'agriculture cellulaire n’appartient pas au futur. Elle est déjà là », a déclaré le Dr. Hamid Noori, CEO de The Cultivated B. « Les autorisations récemment accordées par USDA pour les producteurs de viande cultivée montrent que ce secteur de l'industrie progresse rapidement. Néanmoins, les producteurs ne peuvent pas faire évoluer leurs percées scientifiques et réglementaires du laboratoire à la production commerciale sans avoir la possibilité d'acheter et d'exploiter facilement des bioréacteurs. TCB révolutionne l'industrie de deux manières: premièrement, en rendant ses bioréacteurs disponibles avec des délais de livraison de seulement deux à quatre semaines; et deuxièmement, en concevant un bioréacteur qui peut être utilisé par des non-experts avec seulement quelques jours de formation. Nous changeons la donne pour l'industrie de l'agriculture cellulaire. » Les bioréacteurs AUXO V de TCB offrent une combinaison unique d'utilité et de durabilité. Contrairement aux bioréacteurs de laboratoire traditionnels, les bioréacteurs AUXO V ont été conçus et repensés par des designers industriels pour les rendre faciles à utiliser par des non-experts. Grâce à un système d'interface homme-machine et un Programmable Logic Controller (PLC) de Siemens, le personnel de production peut être formé en quelques jours à l'utilisation du système de contrôle du bioréacteur, traditionnellement réservé aux scientifiques. Les conceptions et le fonctionnement des bioréacteurs AUXO V ont été optimisés par des experts, en accordant une attention particulière aux subtilités de la précision mécanique, à la nature cruciale de l'expérience utilisateur de l'opérateur et aux défis traditionnels tels que les problèmes de contamination. Les nouveaux systèmes de bioréacteurs se concentrent également sur la durabilité, principalement en éliminant l'approche industrielle traditionnelle des bioréacteurs à usage unique. En effet, les bioréacteurs AUXO V sont fabriqués en acier inoxydable de haute qualité, ce qui les rend stérilisables et réutilisables. Leur conception optimise également l'utilisation des matériaux et vise à minimiser l'empreinte carbone de leur fabrication. Les cuves bioréacteurs multi-usages AUXO V sont économiques, flexibles et personnalisables. Ils sont disponibles dans une large gamme de tailles allant de l'échelle de laboratoire à l'échelle industrielle (jusqu'à 25 000 litres) et sont équipés de plusieurs capteurs et d’ impellers optimisés pour différents organismes, tels que les cellules animales, les bactéries ou les levures. De plus, chaque impeller est livré avec un certificat de précision, qui garantit des propriétés de mécanique des fluides optimales pour les bioréacteurs. Servant à présent de catalyseur pour l’avancement de l'agriculture cellulaire, le site de production de Burlington de TCB s'étend sur 130 000 mètres carrés et sur trois étages, et bénéficie d’un emplacement privilégié dans la région de Toronto, qui abrite l'un des plus grands clusters de l’industrie des aliments et de boissons en Amérique du Nord. L'entreprise estime que plus de 200 employés canadiens fabriqueront des bioréacteurs AUXO V pour produire des protéines alternatives à grande échelle. Pour plus d'informations sur les bioréacteurs de The Cultivated B, visitez: https://www.thecultivatedb.ca/manufacturing/ About The Cultivated B (TCB) The Cultivated B’s multinational team of scientists develops and applies breakthrough technologies in cellular agriculture, precision fermentation and advanced bioreactor technology to enable scalable commercialization of the cellular-agriculture industry. TCB serves startups, corporations and academic research institutions within the food, pharma, cosmetics and personal care industries. With its pioneering engineering and production capabilities, TCB enables other companies to produce alternative proteins, such as cultivated meat, at industrial scale. The company’s fundamental commitment to minimizing the natural resources used paves the way toward a sustainable future, locally, regionally and globally. TCB’s research and development team is based in Germany, with manufacturing and an innovation hub based in Canada’s Toronto region. For more information, visit https://www.thecultivatedb.com and follow the company on LinkedIn. Contact Details Jenna Beaucage +1 508-340-6851 tcb@rainerco.com Company Website https://www.thecultivatedb.com

July 19, 2023 08:06 AM Eastern Daylight Time

Image

Debut of Industrial-grade Bioreactor from The Cultivated B Signals Commercial Viability for Cellular Agriculture Industry

The Cultivated B

The Cultivated B (TCB) today announced the availability of its groundbreaking AUXO V ™ industrial-grade bioreactor and the start of rapid-delivery manufacturing at the company’s Burlington, Ontario plant. These represent significant milestones not only for TCB, but more importantly they address the cellular agriculture industry’s urgent need to dramatically increase global capacity in order to reach commercially viability. Because bioreactor delivery times from other vendors can be as much as two years, producers of cultivated meats, medicines and personal care products based on cellular agriculture and precision fermentation face challenges in scaling up from the lab to commercial manufacturing. TCB intends to solve that barrier to industry growth with bioreactor delivery times of just a few weeks, as well as novel, easy-to-use designs that make equipment operator training and skills transfer quick and uncomplicated. “Cellular agriculture is not a thing of the future. It has arrived,” said Dr. Hamid Noori, CEO of The Cultivated B. “The recent USDA approvals for cultivated meat producers are evidence that the industry is quickly advancing, but producers can’t scale their scientific and regulatory breakthroughs from the lab to commercial production without the ability to readily purchase and easily operate bioreactors. TCB is disrupting the industry in two ways: first, by aiming to make our industrial-grade bioreactors available with delivery times of only two to four weeks; and second, by designing a bioreactor that can be operated by non-experts with only a few days of training. We’re changing the game for the cellular agriculture industry.” TCB’s AUXO V bioreactors offer a unique combination of utility and sustainability. Unlike traditional laboratory bioreactors, AUXO V bioreactors were engineered and reimagined by industrial designers to make them easy to use by non-experts. With a human-machine interface and programmable logic controller (PLC) system from Siemens, production personnel can be trained in just a few days to use the bioreactor control system, something traditionally reserved for scientists. The designs and operation of the AUXO V bioreactors were optimized by experts, paying close attention to subtleties of mechanical precision, the crucial nature of operator user-experience, and traditional challenges such as contamination issues. The new bioreactor systems also focus on sustainability, primarily by eliminating the industry’s traditional single-use approach to bioreactors. Instead, AUXO V bioreactors are made of high-grade stainless steel, which makes them sterilizable and reusable. The designs also optimize use of materials and are meant to minimize manufacturing carbon footprint. The AUXO V multi-use bioreactor vessels are cost-effective, flexible and customizable. They are available in a wide range of sizes from lab scale to industrial scale (up to 25,000 liters) and are equipped with multiple sensors and optimized impellers for different organisms, such as animal cells, bacteria or yeast. In addition, every impeller comes with a certificate of accuracy, which ensures optimal fluid mechanical properties of the bioreactors. Now serving as an immediate catalyst for advancement in cellular agriculture, TCB's Burlington plant spans 130,000 square feet across three floors and benefits from its location in the Toronto region, home to one of the largest food and beverage clusters in North America. The company estimates that more than 200 Canadian employees will be manufacturing AUXO V bioreactors to produce alternative proteins at scale. For more information about The Cultivated B’s bioreactors, visit: https://www.thecultivatedb.ca/manufacturing/ About The Cultivated B (TCB) The Cultivated B’s multinational team of scientists develops and applies breakthrough technologies in cellular agriculture, precision fermentation and advanced bioreactor technology to enable scalable commercialization of the cellular-agriculture industry. TCB serves startups, corporations and academic research institutions within the food, pharma, cosmetics and personal care industries. With its pioneering engineering and production capabilities, TCB enables other companies to produce alternative proteins, such as cultivated meat, at industrial scale. The company’s fundamental commitment to minimizing the natural resources used paves the way toward a sustainable future, locally, regionally and globally. TCB’s research and development team is based in Germany, with manufacturing and an innovation hub based in Canada’s Toronto region. For more information, visit https://www.thecultivatedb.com and follow the company on LinkedIn. Contact Details Rainier Communications for TCB Jenna Beaucage +1 508-340-6851 tcb@rainierco.com Company Website https://www.thecultivatedb.com

July 19, 2023 08:05 AM Eastern Daylight Time

Image

News Release

Best Hearing Aids: Read Consumer Reports For Best Over The Counter Hearing Aids

Allied PR

Officially, OTC hearing aids are available for purchase. Previously, people purchased hearing aids primarily from audiologists or other hearing professionals. The new devices are convenient and usually cost-effective for those with mild or moderate hearing loss, although not always. Research carefully before making a rash purchase Consider customization level, battery type, return policy, and smartphone app requirement. The price ranges from around $200 to almost $2,000 per pair. We've analyzed these features for various OTC hearing aid brands. Not an exhaustive list, but here are some key industry players: Audien Atom - Editor’s Pick for Enhance Hearing Overall Chosgo Hearing - Most User-Friendly Hearing Aid Fisdemo - Easiest to Use Hearing Aids for Severe Hearing Loss Otofonix - Best Options for Hearing Aids 1. Audien Atom - Editor’s Pick for Enhance Hearing Overall in USA What is Audien Atom? It is the tiniest and cheapest hearing aid option. Audien Atom is a compact and comfortable device with all the necessary technologies and features to enhance hearing. It is a cost-effective, patent-pending hearing aid that can also reduce bothersome ringing noises. The device will fit snugly into your ears even if it is not specifically designed for your ear canal. It is crucial as it will affect the audio quality too. The Atom's compact size and skin tone enable discrete wearing. It is sleeker and more compact than many expensive hearing aids available. (LOWEST PRICE ONLINE) Click Here to Buy Audien Atom For The Lowest Price Today Working Simple hearing aids include a speaker, amplifier, and microphone that enhance speech comprehension and reduce background noise. Atom enhances and distills core hearing aid design principles. It is offered at the lowest possible price by cutting out intermediaries and their high costs. Simply turn on and place the hearing amplifiers in the ears, after removing them from the charging dock. No app is needed for amplifying a frequency or muffling noise. It requires just a single button to power on/off and adjust the level. Atom can restore your hearing instantly if you've noticed it declining, as if you always have earplugs in your ears. It's a great option for those in the gray area. Features Unparalleled High-Quality Sound: Experience a New Level of Audio The Atom is cozy, indeed. Yes, it is virtually invisible. Indeed, one charge suffices for all-day usage. Above all, Atom works. The advanced features of the Audien Atom deliver enhanced audio clarity for your constant enjoyment. Atom ensures every syllable is heard. Remains charged for a long time Don't worry about batteries dying or running out. Atom is both strong and the most reliable hearing aid available. Quick charge atom with USB-C, long-lasting 20-hour wireless battery, and magnetic connection. The chic, portable charging case adds an extra four days of battery life to the Atom Pro. Low Visibility Design The Atom hearing aid is the tiniest in its category. They disappear into the ear canal, making them unnoticeable. They are incredibly comfortable, so much so that you might forget you're wearing them. Hassle-Free The Hassle-Free Hearing Atom is safe for everyone because no hearing test or prescription is required. Conveniently order online for quick delivery to your door! Specifications Height x Length of the top - 1.4 cm x 0.9 cm Bottom dimensions - 0.4 cm H x 0.4 cm L (inserts into the ear). Weight - 1.9 grams Type - ITC For Mild to moderate hearing loss Battery type - Rechargeable Bluetooth compatibility - No Charging time: 4-6 hours. Battery life: 20-hours Bluetooth charging - yes 22% smaller EV1 earbuds, six extra sets. Sound - Clear, crisp Patent for comfortable design. Package includes a transport bag and wax-infused brush guards with three points. 2. Chosgo Hearing - Most User-Friendly Hearing Aid in USA & UK Chosgo is a direct-to-customer traditional manufacturer, eliminating the intermediary entirely for no additional audiologist, rent, and overhead expenses. The company stocks top-notch chips and regularly updates its technology for the finest quality over-the-counter hearing aids, enhancing your life's quality. (AMAZING DISCOUNT) Get Chosgo Hearing Aids For The Lowest Price Here Features Size - Tiniest available Smart U Rechargeable Hearing Aids Easier control with Bluetooth app Free shipping 45 days free trial Fast delivery 1 year warranty Free Lifetime Support Money back guarantee Benefits Chosgo excels in sound quality with an upgraded digital chip. Chosgo 12-channel hearing aids improve sound reception across multiple frequency bands, ensuring you don't miss conversations with loved ones. Chosgo hearing aids have a chip that reduces background noise, making it easier for you to hear in noisy environments. Helps you hear better. Chosgo excels in being lightweight and compact. It offers a discreet fit for unnoticed hearing aid use. The Chosgo hearing aids are smaller and lighter compared to other models. A solitary earpiece weighs only 2g. Easily worn all day. Chosgo hearing aids have an adjustable switch. They are controlled by one-button buttons rather than traditional mechanical switches. 8 volume levels for customization, switch on/off with long press, control volume with short press. Chosgo hearing aids offer a consistent output, eliminating the need for frequent adjustments with a screwdriver. Stress-free Charging: 24-hour battery life and 128-hour wireless charging box. Battery replacement is not required for 2-3 days. Charging the hearing aid should only be done while resting to ensure storage and charging synchronize. Charging time ranges from 2-4 hours. It charges automatically while you're asleep. What is in the package? The package includes the following: 6 pairs of ear caps for hearing aids 4 pairs of cerumen caps charging cables cleaning brushes Select appropriately sized ear caps for a more comfortable and convenient fit of your hearing aids. The company offers cleaning brushes and cerumen caps to prolong the lifespan of your hearing aids. Its after-sales service is available 24/7 with exceptional quality. It believes in solving problems directly, one-on-one. 3. Fisdemo - Easiest to Use Hearing Aids for Severe Hearing Loss Fisdemo Hearing Aids improves customers' quality of life with innovative hearing solutions. Its dedicated audiologists and technicians provide personalized care and support to enhance your hearing and quality of life. Standard hearing aids are prohibitively expensive for consumers in the hearing aid industry. Some people have friends or parents lacking the means to buy suitable hearing aids or replace a lost one. The cost of conventional hearing solutions and the difficulty in finding affordable alternatives is surprisingly very high. The hearing aid market incentivizes the purchase of expensive products from large corporations through a network of various entities. Thus, the company created Fisdemo as another option. It produces reasonably priced, top-notch hearing aids developed by audiologists and hearing experts because it believes everyone should have equal access to hearing. Making affordable hearing aids alone is inadequate. The company also offers outstanding customer service. Online shopping for hearing aids adds to the challenge. Fisdemo's offering includes exceptional local customer service, complimentary shipping, and a 45-day refund policy. Here are the models offered by the company - Fisdemo Nature Self-Fitting FDA-Cleared OTC Adult Hearing Aids - Most Nature Sound, Rechargeable, Virtually Invisible Fit for Mid to Moderate Hearing Loss Key Features Customize your hearing experience with HA-Fit mobile APP. RIC - In-ear receiver minimizes distortion and feedback, leading to clear and natural sound. Fisdemo Omni has a virtually invisible and lightweight golden beige design. Unnoticeable and comfortable for all-day wear, unknown to anyone. Fisdemo Nature is rechargeable, providing a fast recharge and all-day battery life. The fully charged hearing aids last for over 36 hours, requiring only 2 hours to charge. The portable charging box is easy to transport. Click here to order Fisdemo Nature Self-Fitting OTC Adult Hearing Aids Fisdemo M OTC Rechargeable Hearing Aids for Adults and Seniors with Invisible Fit and All-Day Comfort, Dual Microphone, 35 hours Battery Life, Noise Reduction and Nature Sound Customize your listening experience with 4 programs and 8 volume levels for background noise reduction. Fast and Rechargeable: A 2-hour charge offers 35 hours of standby. Fisdemo M is suitable for mild to moderate hearing loss, offering a maximum sound gain of 40±5 db and effectively eliminating whistling noise with advanced feedback canceling technology. Convenient controls: User-friendly push button for effortless adjustments Crystal-clear audio: Advanced digital chip enhances language clarity, reduces noise, and promotes effortless and enjoyable listening. Click Here to Buy Fisdemo M OTC Rechargeable Hearing Aids Fisdemo Beau Rechargeable Invisible OTC Hearing Aids with Noise Canceling for Adults Seniors (pair), 2 in 1 Charging Box with free Charger and Dryer Improved hearing and comfort: A hearing aid can amplify sounds for comfortable listening if you have mild to moderate hearing difficulties. Usually, it takes a week to adapt to the new sound provided by these aids. Noise reduction: Aids with automatic optical in-ear detection. It turns on when worn and turns off when taken out. Automatically transition to the previous debug mode upon insertion. Earphone box dries quickly: The heat emission holes automatically dry the earphone box after charging, prolonging the lifespan of your hearing aids - extra earbud storage for convenient transport. Battery: The earphone case has a rechargeable battery with a 38 hour battery life and can be fully charged in 2-3 hours, allowing for 4 charging cycles. The hearing enhancement device provides 38 hours of complete sound support. Charger case included: No need to buy new batteries. The case functions well and indicates the charging status clearly. It's effortless to position them correctly and determine charging status instantly. Ear domes - Soft, flexible ear domes improve sound quality and offer a comfy fit by conforming to your ear canals. Easily fitted and removable, five pairs are available. Choose the suitable size, style, and color for your needs. View Pricing & Availability of Fisdemo Beau Rechargeable Invisible OTC Hearing Aids Fisdemo Fort Pro Rechargeable Hearing Aid Behind the Ear with Portable Charger Superb clarity: The small, high-tech gadget offers exceptionally clear sound. Cutting-edge digital equipment enables higher-quality vocal projection for individuals with mild to severe hearing loss. All day use: It has low distortion, medium power output, and a low battery indicator. Comfortable and discreet: Equipped with a Dual Super-Cardioid Polar Pattern Microphone for an enjoyable listening experience. 45-day refund policy on Fisdemo Hearing Aids: Return within 45 days if unsatisfied for a full refund. Buy Fisdemo Fort Pro Rechargeable Hearing Aid For an Unbelievable Low Price Today! 4. Otofonix - Best Options for Hearing Aids in USA & UK Custom hearing aids are the best but expensive. If cost isn't a concern, go for them. Yet, many individuals find the expense of personalized hearing aids to be a major obstacle in improving their auditory experience. A team of audiologists at the company conducted numerous hearing tests prior to creating the amplification profiles embedded in every Otofonix hearing aid. The hearing device experience rivals expensive aids at a fraction of the cost with advanced digital technologies, volume switch, and program selection buttons. Click Here to Get Otofonix Hearing Aids From Its Official website There are three popular models available. These are: 1. Elite - Affordable The Elite is ideal for mild to moderate hearing loss, offering superior sound quality and background noise reduction. Our advanced technology enhances speech clarity by reducing background noise, ensuring understanding in challenging listening environments. 2. Encore - Telecoil The Otofonix Encore Hearing Aid is ideal for individuals with challenges in hearing during one-on-one conversations, over distances, amidst background noise, and experiencing notable word clarity issues. Clear sound is guaranteed in any environment with advanced noise reduction technology. You can tailor your hearing experience to suit your specific needs with 3 programs, an additional Telecoil feature program, and 10 volume levels. 3. Helix - Rechargeable It is the newest, most popular and rechargeable hearing aid. The Helix ensures the best listening experience on the go. It is equipped with advanced noise cancellation and enhanced speech comprehension for complete auditory clarity regardless of ambient noise. Key Features of Good Hearing Aids 43 percent of hearing aid users prioritize smartphone compatibility when buying their current devices. Rechargeable batteries, deemed important by 31 percent, come in second place. Approximately 20% of users consider wireless connectivity or automatic noise level adjustments to be important features. Additional helpful features include: Telecoil A telecoil is a small sensor or copper wire found in many modern hearing aids, providing an option. It converts wireless magnetic signals from hearing-aid-compatible devices into sound. A hearing loop emits a signal for a telecoil to pick up, consisting of an audio induction loop of wire encircling the room or space. This technology aids individuals with hearing loss, facilitating improved comprehension of the speaker's voice by amplifying it and reducing background noise and reverberation. Request a manual T-switch from your provider to connect to loop systems. Your provider must activate and demonstrate telecoil usage. Directional Microphone Directional microphones in modern hearing aids amplify front audio more than back or side noise. This technology is most effective in close proximity to the sound source. Most hearing aids with this feature can automatically toggle between directional and omnidirectional settings based on the surroundings. Advanced versions can have rear or side focus. Con: Wind noise is easily picked up. Feedback Suppression Feedback suppression reduces high-pitched whistling sounds. Various hearing aids have this feature, but its effectiveness varies. It helps reduce feedback when you are near the phone or when the device moves slightly from your ear as you move your jaw. It can enhance ventilation, comfort, and audio quality for listeners with excellent low-frequency hearing. A correct fit can minimize feedback. Digital Noise Reduction This reduces background noise, improving listener comfort and communication in noisy environments. It enhances speech clarity but is not a solution for every circumstance. Best OTC Hearing Aids - Conclusion Hearing aids enhance your hearing through amplification and improved clarity. Hearing aids contain a microphone, an amplifier, and a receiver for improved sound transmission into the ear canal. Microphones send sound to a chip that enhances volume and corrects frequencies for better hearing. Analog aids are simpler and less prevalent than digital aids, but they offer the benefit of fewer advanced features. That can enhance their user-friendliness. A professional can calibrate a digital device for your hearing, reducing wind and background noise while adjusting it to your unique hearing loss. Hearing aids can wirelessly sync with your smartphone for caller, audio streaming, and app-based adjustment. The ideal device depends on factors like your hearing loss, lifestyle, and manual dexterity. Hearing aids that suit one person may not suit another, despite similar audiograms. Also note that hearing aids won't fully eliminate background noise, enabling you to solely hear the speaker(s). It will restore hearing, but not to normal levels. Finding the right hearing aid is difficult due to the potential variability in models, even within the same brand. Hopefully, this guide has offered you enough information to help you find a hearing aid source and identify important criteria for purchase. Contact Details Melissa support@jollofnews.com

July 19, 2023 06:26 AM Eastern Daylight Time

Healthcare

IQ-AI Limited shares latest progress from Phase I glioblastoma clinical trial

Race Oncology announces deal with manufacturer Ardena to develop company’s new IV formulation RC220

Futura Medical "absolutely delighted" with US commercialisation agreement

New Policy Aims to Speed Kidney Acceptance Rates, Increase Transplants

Oxford Cannabinoid Technologies announces "potential breakthrough" in field of oncology

SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?

Le lancement du bioréacteur de The Cultivated B annonce la viabilité commerciale de l'industrie de l'agriculture cellulaire

Debut of Industrial-grade Bioreactor from The Cultivated B Signals Commercial Viability for Cellular Agriculture Industry

Best Hearing Aids: Read Consumer Reports For Best Over The Counter Hearing Aids